ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living With HIV Who Have Adherence Challenges

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced data from a planned interim analysis of the LATITUDE phase III trial, indicating that their long-acting injectable antiretroviral treatment (ART) for HIV, Cabenuva (cabotegravir + rilpivirine), demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of ART adherence c ...